Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
'KRAS': veelvoorkomende mutatie is eindelijk aan te pakken
jul 2021 | Longoncologie